Glaucoma

The Motion Displacement Test (MDT), developed by Moorfields Eye Hospital in partnership with UCL Institute of Ophthalmology and City University London will be on show during World Glaucoma Day (March 12th) to demonstrate some of the latest glaucoma diagnostic equipment.

Dr Tiziana Fattori of Per Vedere Fatti Vedere onlus in Italy explains the reasons behind the launch of a campaign to abolish bureaucratic procedures inhibiting patients from undertaking treatment for glaucoma.

David Garway-Heath examines HRT output as a component in the early glaucoma detection arsenal.

Christopher Girkin discusses how FDT technology predicts disease developments better than SAP.

Neil Choplin considers the importance of retinal nerve fibre loss in early glaucoma.

The Diaton tonometer (BiCOM), a non-invasive and painless way to measure intraocular pressure (IOP) through the eyelid, has been showcased by Phycon Medical at the 2009 meeting of the Florida Osteopathic Medical Association (FOMA).

Dynamic contour tonometry (DCT) may be more accurate than Goldmann applanation tonometry (GAT) in measuring intraocular pressure (IOP), according to study results published in the February issue of Eye.

OPKO Health, Inc has received FDA marketing clearance on an imaging device and launched clinical trials of a new glaucoma shunt, the company has announced.

The National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3RS) has awarded its annual prize to a project exploring the use of stem cells for treating glaucoma and other eye diseases.

A laser-based surgical device has been shown during trials to provide a safe, non-penetrating method of reducing intraocular pressure (IOP), according to study results published by the developer of the device, IOPtima Ltd.

The TrueField Analyser, a glaucoma testing device, has been hailed by reseachers at the Australian National University as offering faster, more comprehensive and more accurate diagnoses than current methods.

CORM-3, a water-soluble carbon monoxide-releasing molecule, is associated with a intraocular pressure (IOP) lowering in animal models of ocular hypertension, concluded a study published in the January issue of the British Journal of Ophthalmology.

Deep sclerectomy with MMC is safer and more effective than trabeculectomy or tube surgery, according to Dr Nitin Anand.

Trabeculectomy with MMC and Ex-PRESS shunt device placement appears to be safer than other treatment methods, according to Dr Leon Herndon.

GlaucomaCheck, an online visual field test allowing for clinical grade at-home glaucoma screening, has been launched by VisionRx.

A clinical trial assessing glaucoma treatment compliance of patients using text and telephone messaging technology has been launched by the Wilmer Eye Institute at Johns Hopkins University, Baltimore, Maryland, US.

Both selective laser trabeculoplasty (SLT) and latanoprost are effective at controlling the level and fluctuation of intraocular pressure (IOP), according to a study published online ahead of print by the British Journal of Ophthalmology.

Penetrating deep sclerectomy (combining deep sclerectomy with trabeculectomy) delivers promising intermediate results in the treatment of paediatric glaucoma, according to the conclusions of a study published in the January issue of Ophthalmology.

Using a risk calculator might impact ocular hypertension treatment options, concluded a study published in the December 2008 issue of the Journal of Ophthalmology.

Latisse (bimatoprost solution 0.03%) (Allergan, Inc) has been recommended for FDA approval as a treatment for hypertrichosis of the eyelashes.

Gingko biloba extract (GBE) has an application in preventing steroid-induced ocular hypertension, according to study results published in the December issue of the Archives of Ophthalmology.

New imaging techniques are allowing more objective quantification of glaucoma diagnosis and progression, according to study results published online ahead of print by the British Journal of Ophthalmology.

Religiously-motivated fasting may affect glaucoma medication compliance rates, according to study results presented at the annual meeting of the American Academy of Ophthalmology (AAO).

Azarga (brinzolamide 10mg/ml and timolol 5mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.

The Pascal dynamic contour tonometer (DCT) and Reichert ocular response analyser (ORA) are the best tools for measuring corneal-compensated intraocular pressure (IOPcc) in patients with keratoconus (KC), according to study results published in the British Journal of Ophthalmology, December.

A multimedia campaign may be the best way to raise glaucoma awareness in the UK, according to study results published in the December issue of the British Journal of Ophthalmology.

It is up to our refractive surgery colleagues to publish their results on such patients to allow us to put some, or all, of our questions to rest.

We should not be adding another drug to the therapeutic mix without having established the efficacy and side effect profile of a single therapy.

Administering fixed combinations as first-line treatment allows us to understand quickly whether our patients are non-responders or insufficient responders.

There is no evidence to suggest that there is rapid glaucoma progression following refractive surgery.